NCT06921044 - A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

March 1, 2027

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone

Rituximab ：375 mg/m2，ivgtt，d0； Mitoxantrone Liposome ： The first dose level: 6mg/m2, ivgtt, d1; The second dose level: 8mg/m2, ivgtt, d1; The third dose level: 10mg/m2, ivgtt, d1; Cyclophosphamide :400 mg/m2，ivgtt，d1； Vincristine :1mg（，ivgtt，d1； Prednisone:40 mg/m2，po.，d1-5； Q3W